Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Evaluating the effects of the OPERA trial in clinical practice

KRAS mutations are present in 90% of pancreatic ductal adenocarcinomas (PDACs). P.G12C accounts for 1-2% of these KRAS mutations. John H. Strickler, MD, Duke Cancer Institute, Durham, NC, provides an overview of the international, single-arm, Phase I/II trial, CodeBreak100 (NCT03600883) exploring the KRAS p.G12C inhibitor, sotorasib, in patients with previously treated pancreatic cancer harboring the KRAS p.G12C mutation. The primary endpoint is confirmed objective response rate (ORR) and secondary endpoints include duration of response (DoR), progression-free survival (PFS) and overall-survival (OS). 38 patients with pancreatic cancer received sotorasib once daily. ORR was 21.1% and DCR was 84.2%, with a PFS of 4 months and median DoR of 6 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.